This study aimed to determine if CD31 is a novel marker of a circulating angio-vasculogenic cell population and to establish the cells' therapeutic effects on experimental ischemia.
Background
Emerging evidence suggested that therapeutic mechanisms underlying various bone marrow-derived cells are due to paracrine effects. Furthermore, the vasculogenic potential of these cells is under debate. CD31 is a wellknown marker for endothelial cells but is also expressed in a fraction of peripheral blood (PB) mononuclear cells.
Methods

CD31
ϩ cells were isolated from human PB by magnetic-activated cell sorting. The gene expression profile was examined by deoxyribonucleic acid microarray and real-time reverse transcriptase polymerase chain reaction. Various in vitro endothelial differentiation or vasculogenic assays were conducted. Finally, cells were directly implanted into a mouse hind limb ischemia model to test angiogenic-vasculogenic and therapeutic effects.
Results
Fluorescent-activated cell sorter analysis revealed that PB-CD31 ϩ cells exhibited endothelial and hematopoietic stem/progenitor markers. CD31 ϩ cells had higher levels of expression of proangiogenic genes on microarray and real-time reverse transcriptase polymerase chain reaction and generated higher numbers of endothelial progenitor cells than CD31 -cells did. CD31 ϩ cells spontaneously formed vascular tubelike structures and exhibited an endothelial cell phenotype in vitro. In a hind limb ischemia model, CD31 ϩ cell transplantation augmented blood perfusion and prevented limb loss. Both angiogenic cytokines and capillary density were increased, suggesting CD31 ϩ cells augmented neovascularization.
Conclusions
CD31 is a novel marker that designates circulating angiogenic and vasculogenic cells. These cells are easily isolated from human PB and thus are a novel candidate for treatment of ischemic cardiovascular disease. Ischemic cardiovascular disease is the most prevalent disease in Westernized society. Despite progress in therapies, nearly 80 million are affected yearly from heart attack, stroke, and ischemic cardiomyopathy (1) . As our knowledge of stem cell biology grows, cell-based therapies have become a promising strategy for tissue regeneration.
Transplantation of various bone marrow (BM)-derived cells, including mononuclear cells (MNCs), endothelial progenitor cells (EPCs), mesenchymal stem cells, and hematopoietic stem cells
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(HSCs), were reported to induce therapeutic neovascularization in adult ischemic tissues (2) (3) (4) (5) . Even though cellbased therapy has great therapeutic potential, several issues remain. The use of unselected BM cells or BM-MNCs was associated with adverse events including calcification, vascular plaque growth, and worsening of tissue ischemia (6 -8) . Both EPCs and mesenchymal stem cells require ex vivo culture to be used clinically. For all BM-derived cells, their ability to (trans)differentiate into endothelial cells (ECs), and the magnitude of their vasculogenic potential, have been debated (9 -11) . Paracrine mechanisms and/or other nondifferentiation effects are the primary mediators of BM-derived cell benefit in ischemic cardiovascular disease (3, (12) (13) (14) and mainly work via augmentation of neovascularization/angiogenesis or improvement of microcirculation. Based on these new discoveries on the mechanisms and adverse effects of various BM cells over the past decade, in this study, we sought to explore whether there is a specific native population of BM cells that possesses higher paracrine or angiogenic activity and, further, to determine the therapeutic potential of this population for treating ischemic cardiovascular diseases. Additionally, given the controversy regarding the (trans)differentiation, we sought to definitively determine whether BM cells are able to give rise to ECs via vasculogenesis. We used rigorous criteria and new experimental techniques to address the main points of criticism from the previous studies that refuted the concept of endothelial differentiation from BM cells (9 -11,15) .
We have found that CD31, a ubiquitous EC marker, is also expressed on the surface of various mouse hematopoietic cell lineages (16) , including HSCs (17) , and undifferentiated mouse embryonic stem cells (18) . CD31, also known as platelet endothelial cell adhesion molecule 1, is a 130-kDa cell surface molecule and a member of the immunoglobulin superfamily (19) . CD31 plays important role for transendothelial leukocyte migration, cell-cell adhesion, and antiapoptotic signaling (20) . However, the therapeutic role of the cells expressing this marker in tissue regeneration is unknown. Based on the conserved expression of CD31 on cells of the hemangioblast lineage, we hypothesized that CD31 ϩ cells in peripheral blood (PB) have higher angiogenic and/or vasculogenic capabilities.
Through a series of in vitro and in vivo experiments, we found that CD31 ϩ cells isolated from PB showed higher angiogenic activity and vasculogenic potential, effectively improving ischemia in mouse hind limb ischemia by augmentation of neovascularization.
Methods
An expanded Methods section is available in the Online Appendix. The following topics are covered there: (Fig. 1B,  Online Fig. 1A ). To investigate the hematopoietic progenitor cell (HPC) properties, a clonogenic assay was performed. CD31 ϩ cells, when compared with CD31 -cells, generated a significantly higher number of hematopoietic colonies such as colony forming unit erythroid, burst forming unit erythroid, colony forming unit granulocyte/macrophage, and colony forming unit granulocyte/erythroid/macrophage/megakaryocyte (p Ͻ 0.05) (Fig. 1C, Online Fig. 1B (21) demonstrated that genes involved in angiogenesis, cell adhesion, transmembrane structure, chemokine production and reception, and extracellular matrix were highly and preferentially expressed in CD31 ϩ cells (Fig. 2B , To confirm the results of microarray data, we performed qRT-PCR analysis. Major angiogenic factors such as vascular endothelial growth factor-A, fibroblast growth factor-2, hepatocyte growth factor, and angiopoietin-1, and an adhesion molecule, VE-cadherin, were more highly expressed in CD31 ϩ cells than in CD31 -cells or MNCs (Fig. 2C ). Chemokines such as monocyte chemoattractant protein-1 and interleukin-8, which play an important role for neovascularization, were also significantly up-regulated (23, 24) . Collectively, these findings show that CD31 ϩ cells define a population enriched with angiogenic, chemoattractant, and cell adhesion genes.
CD31
؉ cells show higher vasculogenic potential and cell adhesion capacity in vitro. We next investigated the in vitro endothelial differentiation potential of CD31 ϩ cells. First, we performed EPC culture assay. The number of EPCs and EPC colonies were markedly higher in the CD31 ϩ cell group than in the CD31
-cell group (all p Ͻ 0.01) (Figs. 3A and 3B). Second, we carried out a cell adhesion assay. The number of adhered cells to various extracellular matrix proteins, fibronectin, vitronectin, collagen I, and laminin was significantly higher in the CD31 ϩ cells than in the CD31 -cells (all p Ͻ 0.001) (Fig. 3C ). In ECs, adhesion capacity is an indicator of cell engraftment and cell survival.
To induce EC differentiation, CD31 ϩ cells were cultured in endothelial growth media 2, which is endothelia cell basal media 2 with 15% FBS and cytokine cocktail (SingleQuots, Lonza Cologne AG, Cologne, Germany), for 28 days.
ϩ cells exhibited EC markers such as von Willebrand factor, kinase insert domain receptor, vascular endothelial cadherin, and CD31 by immunocytochemistry (Fig. 3D ). CD31 -cells were not culturable under these conditions. During this culture, we made an intriguing observation that some CD31 ϩ cells spontaneously formed tubular structures. In the first week of culture, CD31 ϩ cells aggregated; around day 10, the cells started to form tubular structures within the cell clusters; and between days 12 and 16, the cell clusters underwent morphologic changes to form linear tubular structures, mimicking in vivo vasculogenesis (Figs. 3E to 3I). These tubular structures stained positive for lectin and took up 1,1=dioctadecyl-3,3,3=,3=-tetramethylindocarbocyaninelabeled acetylated low-density lipoprotein (DiI-acLDL), characteristics of ECs. We further measured the expression of endothelial and angiogenic genes during the culture of CD31 ϩ cells over 28 days by qRT-PCR. Over 28 days, the expression of kinase insert domain receptor, vascular endothelial cadherin, hepatocyte growth factor, and insulinlike growth factor 1 gradually increased sug- gesting differentiation into a more vasculogenic and angiogenic phenotype (Fig. 3J) The x axis represents the number of differentially expressed genes in a specific category of annotations from our list of 779 genes (generated using multiple comparisons correction: false-discovery rate adjusted p value Ͻ0.05). (C) The expression patterns of multiple angiogenic factors were measured by real-time reverse transcriptase polymerase chain reaction. Data are presented as fold difference compared with the mononuclear cell group. n ϭ 6 per group. *p Ͻ 0.05; **p Ͻ 0.01. ANG ϭ angiopoietin; FDR ϭ false-discovery rate; FGF ϭ fibroblast growth factor; GAPDH ϭ glyceraldehyde-3-phosphate dehydrogenase; HGF ϭ hepatocyte growth factor; IGF ϭ insulinlike growth factor; IL ϭ interleukin; MCP ϭ monocyte chemoattractant protein; MNC ϭ mononuclear cell; PDGF-B ϭ platelet-derived growth factor B; VE-cad ϭ vascular endothelial cadherin; VEGF ϭ vascular endothelial growth factor.
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Angio-Vasculogenic Properties of CD31 ؉ Cells maturation in the ischemic hind limb adductor muscle after surgery was also significantly higher in the CD31 ϩ group than in the CD31 -group or the PBS group (p Ͻ 0.01) (Figs. 5A and 5B, Online Fig. 2 ). We also found that functional capillaries examined after intracardiac injection of isolectin B4 (ILB4) were significantly higher in the CD31 ϩ group than in the other groups (Online Fig. 3 ). In addition, terminal deoxyribonucleotidyl transferase (TDT)-mediated dUTP-digoxigenin nick end labeling (TUNEL) assay, together with ILB4 staining, demonstrated that transplantation of CD31 ϩ cells significantly reduced endothelial cell apoptosis when compared to control groups, suggesting protective effects on existing vessels (Online Fig. 4) . Collectively, these findings suggest that CD31 ϩ cells can augment functional neovascularization and preserve existing vessels in vivo and are effective for treating ischemic vascular disease. Multiple angiogenic factors are up-regulated after CD31 ؉ cells transplantation. To determine the effects of CD31 ϩ cell transplantation on cytokine expression in ischemic hind limbs, mice were sacrificed and hind limb tissues collected. The expression levels of vascular endothelial growth factor-A, angiopoietin-1, fibroblast growth factor-2, stromal cell-derived factor-1, and CD31 were significantly increased in the CD31 ϩ cell-injected limbs compared with the CD31 -cell-or PBS-injected limbs (Fig. 5C ). These data suggest that CD31 ϩ cell transplantation up-regulates the expression of multiple biological factors associated with neovascularization and bone marrow cell mobilization.
Contribution of CD31
؉ cells into vasculogenesis. We further sought to determine the potential and magnitude of the contribution of CD31 ϩ cells to ECs' generation or vasculogenesis. To track the transplanted cells, we intramuscularly injected 1 ϫ 10 6 DiI-labeled CD31 ϩ cells into the ischemic hind limb of nude mice. Histologic analysis demonstrated that a larger part of the injected CD31 ϩ cells were concentrated in the pericytic or perivascular areas (Figs. 6A to 6D, Online Video 1) and a smaller population of CD31 ϩ cells exhibited an EC's specific marker, ILB4, within the vascular structure at 2 to 8 weeks (Figs. 6E to 6G, Online Video 2). This suggests that CD31 ϩ cells generated ECs in vivo. To confirm this, we performed fluorescent in situ hybridization (FISH) using human Y chromosome probe (25, 26) . The FISH data showed that Y chromosome signals from transplanted human CD31 ϩ cells were detected within the nuclei of ECs (Fig. 6I) ECs were derived from transplanted CD31 ϩ cells (Fig. 7A) . Next, to further confirm whether these double positive cells were truly derived from the injected human CD31 ϩ cells, they were subjected to FISH with human Y chromosome. FISH demonstrated that the ILB4-and DiI-positive cells from recipient mice were of human donor origin, confirming differentiation of CD31 ϩ cells into ECs (Fig. 7B) . 
Discussion
In this study, we show that CD31 is a unique and comprehensive marker to represent potent angiogenic and vasculogenic cells in human PB and that these cells are therapeutically effective for recovering tissue from ischemia. First, we demonstrated that human CD31 ϩ cells highly express HSC/HPC and EC markers. Second, CD31
ϩ cells are enriched with proangiogenic genes. Third, compared with CD31 -cells, CD31 ϩ cells generated more EPCs and demonstrated EC differentiation and vascularlike tube formation in culture. Fourth, implantation of CD31 ϩ cells into ischemic hind limb enhanced recovery of tissue from ischemic injury and increased the rate of limb salvage as well as the expression of angiogenic factors. Fifth, implanted CD31 ϩ cells show clear vasculogenic potential in ischemic limb tissues.
Because CD31 is a ubiquitous endothelial marker, we tested the hypothesis that the cells expressing CD31 in PB have angiogenic and/or vasculogenic capabilities. FACS showed that the CD31 ϩ cells expressed HSC/HPC markers and well-known EC markers, suggesting dual properties (Figs. 3E to 3I ). This finding is one of the most unprecedented of this study, supporting the vasculogenic potential of CD31 ϩ cells. These data suggest that CD31 is an antigenic signpost for robust proangiogenic and vasculogenic cells in PB.
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In vivo cell transplantation studies further confirmed these results. CD31 ϩ cell transplantation induced higher expressions of multiple paracrine factors in the ischemic tissues during the critical period of ischemia repair. Our data suggest that the major mechanism of CD31 ϩ cells would be a nondifferentiation mechanism because the rate of endothelial differentiation was too small to account for the magnitude of therapeutic effects seen. CD31 ϩ cells highly expressed crucial angiogenic and arteriogenic factors including vascular endothelial growth factor, angiopoietin-*1, fibroblast growth factor-2, and monocyte chemoattractant protein-1. Synergistic effects of these angiogenic factors have been reported to induce therapeutic neovascularization (27) . In addition, tissues injected with CD31 ϩ cells expressed high levels of stromal cell-derived factor-1, which are known to contribute to a pro-neovascularization environment. For optimal neovascularization, such an environment is required to recruit necessary cell types including monocytes and macrophages (28, 29) . Another characteristic that may make CD31 ϩ cells particularly effective is their high adhesion capacity. Cell adhesion signals control cell viability and are essential for regulated angiogenesis and vasculogenesis via cell-cell and cell-matrix interactions (9, 11, 15) .
The controversy remains regarding the (trans)differentiation potential of BM-derived cells into ECs. To clarify this, we meticulously evaluated hind limb muscles using multiple techniques. First, we used 3-dimensional reconstruction of confocal microscopic images to examine at least 1,200 tissue sections collected from 10 animals from each group. Although most CD31 ϩ cells were localized to the interstitium or perivascular region, some cells were incorporated into vasculature and expressed functional EC markers (Fig. 7A) . Second, FISH using Y chromosome probes showed positive donor cell-derived signals within the nuclei of ECs, suggesting endothelial differentiation of CD31 ϩ cells. Third, FACS analysis confirmed and quantified ECs derived from CD31 ϩ cells injected into hind limb ischemia. The FACS analysis revealed 2.2% of ECs in hind limb muscle were derived from implanted CD31 ϩ cells. We used these techniques to avoid sampling errors inherent in histologic analysis. To the best of our knowledge, this is the first study to employ this technology to prove and quantify endothelial differentiation from injected BM cells. Finally, we further confirmed that these FACS-isolated (trans)differentiated ECs are human origin by FISH. These results indicate that specific populations of PB-MNCs can (trans)differentiate into ECs although the differentiation efficiency is low.
Cell selection using the surface antigen CD31 has several advantages over more specific hematopoietic stem/progenitor markers CD133 ϩ or CD34 (30, 31) . Approximately 80% of CD133 ϩ cells and 85% of CD34 ϩ cells are contained within the CD31 ϩ cell fraction (Fig. 1, Online Fig. 1 ). Thus, CD31
ϩ cells can exert most of the beneficial effects of both cell types while still providing additional paracrine or vascularizing effects through other cell types. Clinically, as CD31 ϩ cells occupy approximately 30% of PB-MNCs, these cells do not require mobilization to obtain enough to be used for cell therapy.
Conclusions
PB-derived CD31
ϩ cells contain robust angiogenic and vasculogenic abilities that ameliorate hind limb ischemia. Although we only showed ischemic limb recovery in this study, this therapy would also be effective for ischemic heart disease given their broad neovascularizing, paracrine, and cell adhesion capacities. Accordingly, these cells can serve as a highly promising and novel therapeutic option for ischemic cardiovascular disease. Further investigation will be needed to determine if CD31 ϩ cells are capable of treating human ischemic cardiovascular diseases.
